← Back to Search

Anti-malarial drug

Chloroquine Phosphate for Atrial Fibrillation

Phase 2
Recruiting
Led By Sami Noujaim, PhD
Research Sponsored by University of South Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 2 weeks of study drug initiation
Awards & highlights

Study Summary

The goal of this pilot study is to explore the efficacy of chloroquine in terminating persistent AF and assess its potential role as a pharmacological cardioversion agent for the management of AF.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 2 weeks of study drug initiation
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 2 weeks of study drug initiation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of patients with termination of AF
Secondary outcome measures
PR interval
Percentage of AF burden
Percentages of classifications of rhythms identified
+3 more

Side effects data

From 2021 Phase 1 & 2 trial • 252 Patients • NCT03952650
61%
Rhinitis
53%
Headache
53%
Malaria
47%
Blood creatinine increased
36%
Leukopenia
31%
Neutropenia
22%
Conjunctivitis
17%
Gastroenteritis
14%
Oropharyngeal pain
11%
Back pain
11%
Sinobronchitis
11%
Gastritis
11%
Wound
8%
Dental caries
8%
Abdominal pain
8%
Dizziness
8%
Ear infection
8%
Paronychia
8%
Pain
6%
Decreased appetite
6%
Bronchitis
6%
Furuncle
6%
Injection site pain
6%
Hemoglobin decreased
6%
Nausea
6%
Respiratory tract infection
3%
Candidiasis
3%
Injury
3%
Vaginal haemorrhage
3%
Arthralgia
3%
Genitourinary tract infection
3%
Influenza
3%
Parasitic gastroenteritis
3%
Tonsillitis
3%
Urticaria
3%
Vessel puncture site pain
3%
White blood cell count increased
3%
Wound infection
3%
Ecchymosis
3%
Typhoid fever
3%
Urinary tract infection
3%
Diarrhea
3%
Cough
3%
Food poisoning
100%
80%
60%
40%
20%
0%
Study treatment Arm
4b - Safety Comparator: Dosing Interval on Days: 1, 29, 57
2b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57
3a - Pilot/Safety: Dosing Interval on Days: 1
4a - Safety Comparator: Dosing Interval on Days: 1, 29, 57
1a - Pilot/Safety: Dosing Interval on Days: 1
1b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57
2a - Pilot/Safety: Dosing Interval on Days: 1

Trial Design

1Treatment groups
Experimental Treatment
Group I: Chloroquine PhosphateExperimental Treatment1 Intervention
Chloroquine Phosphate will be provided at 500 mg dosage strength for oral administration. Patient will be instructed to take 2 tablets per day on the first two days and 1 tablet each day for the next 12 days for a total of 14 days treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Chloroquine
FDA approved

Find a Location

Who is running the clinical trial?

University of South FloridaLead Sponsor
411 Previous Clinical Trials
186,989 Total Patients Enrolled
1 Trials studying Atrial Fibrillation
91 Patients Enrolled for Atrial Fibrillation
Sami Noujaim, PhDPrincipal InvestigatorUniversity of South Florida

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study
2017. "Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02932007.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top